NXTC Q2 2019 Earnings — NextCure, Inc. Revenue & Financial Results | Market Cap Arena

NXTCNextCure, Inc.

$35M

Q2 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M

Gross Profit

-$6M-445.1% margin

Operating Income

-$9M-638.7% margin

Net Income

-$8M-586.4% margin

EPS (Diluted)

$-7.31

QoQ Revenue Growth

+3.3%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$12M

Stock-Based Comp.

$412,000

Balance Sheet

Total Assets

$213M

Total Liabilities

$34M

Stockholders' Equity

$179M

Cash & Equivalents

$193M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$0	—
Gross Profit	-$6M	-$4M	-40.8%
Operating Income	-$9M	-$5M	-69.0%
Net Income	-$8M	-$5M	-57.2%